SBC Medical Group (NASDAQ:SBC) Upgraded to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded SBC Medical Group to “Hold,” adding to a mixed analyst picture that includes two Buy ratings, one Sell rating, and an average Wall Street target price of $8.50.
• The stock was trading at $3.18, down 0.9%, with shares near their 12-month low of $2.97 and well below the consensus target price. SBC also has a relatively low debt-to-equity ratio of 0.13 and a market cap of about $326.2 million.
• Recent results showed mixed fundamentals: SBC Medical Group beat EPS expectations at $0.14 per share, but revenue of $39.57 million came in below estimates. CEO Yoshiyuki Aikawa also sold 465,000 shares in late April, while institutional ownership remains high at 60.82%.

SBC Medical Group (NASDAQ:SBC - Get Free Report) was upgraded by investment analysts at Wall Street Zen to a "hold" rating in a note issued to investors on Saturday.

A number of other research firms also recently weighed in on SBC. BTIG Research began coverage on shares of SBC Medical Group in a research report on Friday, March 6th. They issued a "buy" rating and a $8.00 target price on the stock. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of SBC Medical Group in a research report on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $8.50.

SBC Medical Group Stock Down 0.9%

Shares of SBC Medical Group stock opened at $3.18 on Friday. The company has a current ratio of 3.78, a quick ratio of 3.74 and a debt-to-equity ratio of 0.13. The company's fifty day simple moving average is $3.84 and its two-hundred day simple moving average is $3.96. The company has a market cap of $326.20 million, a P/E ratio of 6.49 and a beta of 0.61. SBC Medical Group has a 12-month low of $2.97 and a 12-month high of $5.75.

SBC Medical Group (NASDAQ:SBC - Get Free Report) last issued its quarterly earnings data on Friday, March 27th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.13 by $0.01. The business had revenue of $39.57 million for the quarter, compared to the consensus estimate of $45.19 million. SBC Medical Group had a net margin of 29.37% and a return on equity of 20.76%. Research analysts anticipate that SBC Medical Group will post 0.47 EPS for the current year.

Insider Buying and Selling at SBC Medical Group

In other news, CEO Yoshiyuki Aikawa sold 465,000 shares of the company's stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $3.02, for a total value of $1,404,300.00. Following the sale, the chief executive officer directly owned 78,839,460 shares of the company's stock, valued at $238,095,169.20. This represents a 0.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders have sold 7,987,900 shares of company stock valued at $20,142,848. 89.47% of the stock is owned by corporate insiders.

Institutional Trading of SBC Medical Group

Institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp purchased a new stake in SBC Medical Group during the 1st quarter valued at about $43,000. Goldman Sachs Group Inc. purchased a new stake in SBC Medical Group during the 4th quarter valued at about $49,000. Russell Investments Group Ltd. grew its position in SBC Medical Group by 292.0% during the 4th quarter. Russell Investments Group Ltd. now owns 11,775 shares of the company's stock valued at $51,000 after purchasing an additional 8,771 shares during the last quarter. Nuveen LLC purchased a new stake in SBC Medical Group during the 4th quarter valued at about $53,000. Finally, Wells Fargo & Company MN grew its position in SBC Medical Group by 195.1% during the 4th quarter. Wells Fargo & Company MN now owns 12,626 shares of the company's stock valued at $54,000 after purchasing an additional 8,348 shares during the last quarter. 60.82% of the stock is owned by hedge funds and other institutional investors.

SBC Medical Group Company Profile

SBC Medical Group, Inc is a publicly traded healthcare management services company listed on the Nasdaq under the ticker SBC. The company specializes in supporting in-office ancillary service providers by offering a suite of administrative and operational solutions designed to streamline practice management and enhance revenue performance. Its core mission is to help physician practices, imaging centers and other ancillary service providers focus on patient care while outsourcing complex back-office functions.

The company's primary offerings include revenue cycle management, medical billing and coding, compliance oversight and transcription services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.